Literature DB >> 12461428

Diurnal variation of plasma protease inhibitor concentrations.

Ulrik S Justesen1, Court Pedersen.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12461428     DOI： 10.1097/00002030-200212060-00019

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  11 in total

1.  Influence of SLCO1B1 polymorphisms on lopinavir Ctrough in Serbian HIV/AIDS patients.

Authors:  Gordana Dragović; Božana Dimitrijević; Jovana Kušić; Ivan Soldatović; Djordje Jevtović; Adeniyi Olagunju; Andrew Owen
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

2.  Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

Authors:  R P G van Heeswijk; M Bourbeau; I Seguin; P Giguere; G E Garber; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

3.  Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

Authors:  Chao Zhang; Paolo Denti; Eric Decloedt; Gary Maartens; Mats O Karlsson; Ulrika S H Simonsson; Helen McIlleron
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

4.  Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Authors:  Eric H Decloedt; Helen McIlleron; Peter Smith; Concepta Merry; Catherine Orrell; Gary Maartens
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.

Authors:  Lawrence S Lee; Anushia Panchalingam; Marline C Yap; Nicholas I Paton
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Authors:  Esteban Ribera; Rosa M Lopez; Marjorie Diaz; Leonor Pou; Lidia Ruiz; Vicenç Falcó; Manuel Crespo; Carlos Azuaje; Isabel Ruiz; Imma Ocaña; Bonaventura Clotet; Albert Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 7.  Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Authors:  Rob E Aarnoutse; Jonathan M Schapiro; Charles A B Boucher; Yechiel A Hekster; David M Burger
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Authors:  Fenglei Huang; Kristin Drda; Thomas R MacGregor; Joseph Scherer; Lois Rowland; Thuy Nguyen; Charles Ballow; Mark Castles; Patrick Robinson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Authors:  Brian L Robbins; Edmund V Capparelli; Ellen G Chadwick; Ram Yogev; Leslie Serchuck; Carol Worrell; Mary Elizabeth Smith; Carmelita Alvero; Terence Fenton; Barbara Heckman; Stephen I Pelton; Grace Aldrovandi; William Borkowsky; John Rodman; Peter L Havens
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

10.  Adherence to anti retroviral therapy (ART) during Muslim Ramadan fasting.

Authors:  A G Habib; J C Shepherd; M K L Eng; M Babashani; J Jumare; U Yakubu; U I Gebi; M Saad; H Ibrahim; W A Blattner
Journal:  AIDS Behav       Date:  2008-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.